These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31035664)

  • 1. Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer.
    Xie H; Paradise BD; Ma WW; Fernandez-Zapico ME
    Cells; 2019 Apr; 8(5):. PubMed ID: 31035664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
    Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
    Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Hedgehog Antagonists for Cancer Therapy.
    Khatra H; Bose C; Sinha S
    Curr Med Chem; 2017; 24(19):2033-2058. PubMed ID: 28302010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications.
    Grund-Gröschke S; Stockmaier G; Aberger F
    Cell Commun Signal; 2019 Dec; 17(1):172. PubMed ID: 31878932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
    Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
    Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers.
    Katoh M
    Clin Sci (Lond); 2019 Apr; 133(8):953-970. PubMed ID: 31036756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
    Berardozzi S; Bernardi F; Infante P; Ingallina C; Toscano S; De Paolis E; Alfonsi R; Caimano M; Botta B; Mori M; Di Marcotullio L; Ghirga F
    Eur J Med Chem; 2018 Aug; 156():554-562. PubMed ID: 30025349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties.
    Wang F; Stappenbeck F; Parhami F
    Cells; 2019 May; 8(5):. PubMed ID: 31137846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
    Pietrobono S; Gaudio E; Gagliardi S; Zitani M; Carrassa L; Migliorini F; Petricci E; Manetti F; Makukhin N; Bond AG; Paradise BD; Ciulli A; Fernandez-Zapico ME; Bertoni F; Stecca B
    Oncogene; 2021 Jun; 40(22):3799-3814. PubMed ID: 33958721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?
    Rovida E; Stecca B
    Semin Cancer Biol; 2015 Dec; 35():154-67. PubMed ID: 26292171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.
    Carpenter RL; Ray H
    Drug Saf; 2019 Feb; 42(2):263-279. PubMed ID: 30649745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cancer hallmark vulnerabilities in hematologic malignancies by interfering with Hedgehog/GLI signaling.
    Krenn PW; Aberger F
    Blood; 2023 Dec; 142(23):1945-1959. PubMed ID: 37595276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting GLI Transcription Factors in Cancer.
    Didiasova M; Schaefer L; Wygrecka M
    Molecules; 2018 Apr; 23(5):. PubMed ID: 29695137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
    Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
    Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.
    Arnhold V; Boos J; Lanvers-Kaminsky C
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):495-505. PubMed ID: 26781311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of hedgehog/Gli signaling by botanicals: a review of compounds with potential hedgehog pathway inhibitory activities.
    Drenkhahn SK; Jackson GA; Slusarz A; Starkey NJ; Lubahn DB
    Curr Cancer Drug Targets; 2013 Jun; 13(5):580-95. PubMed ID: 23675897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer.
    Mazumdar T; DeVecchio J; Agyeman A; Shi T; Houghton JA
    Oncotarget; 2011 Aug; 2(8):638-45. PubMed ID: 21860067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.
    Manetti F; Petricci E
    Expert Opin Ther Pat; 2016; 26(4):529-35. PubMed ID: 26666870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to target the Hedgehog signaling pathway for cancer therapy.
    Xin M; Ji X; De La Cruz LK; Thareja S; Wang B
    Med Res Rev; 2018 May; 38(3):870-913. PubMed ID: 29315702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic: a potentially useful poison for Hedgehog-driven cancers.
    Raju GP
    J Clin Invest; 2011 Jan; 121(1):14-6. PubMed ID: 21183780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.